Debrisoquine


Full Generic Medicine Info
Dosage/Direction for Use

Oral
Hypertension
Adult: 10-20 mg once-bid, increased by 10-20 mg every 3 or 4 days according to severity of condition. Maintenance: 20-120 mg daily.
Max Dosage: ≥300 mg daily.
Contraindications
Phaeochromocytoma, heart failure.
Special Precautions
Renal impairment, coronary or cerebral arteriosclerosis, asthma, history of peptic ulceration, pregnancy. Abrupt cessation may lead to rebound hypertension.
Adverse Reactions
Postural hypotension, failure of ejaculation, fluid retention, nasal decongestion, headache, diarrhoea, drowsiness.
Drug Interactions
Adrenaline, amfetamine, other sympathomimetics, TCAs, MAOIs, phenothiazine derivatives and related antipsychotics, oral contraceptives, digoxin or other digitalis derivatives, thiazide diuretics, other antihypertensives, levodopa, alcohol.
Action
Debrisoquine acts by selectively inhibiting transmission in postganglionic adrenergic nerves. It acts mainly by preventing the release of noradrenaline at nerve endings. It does not prevent the catecholamine secretion by the adrenal medulla.
Onset: 4-10 hr.
Duration: 9-24 hr.
Absorption: Rapidly absorbed from the GI tract.
Metabolism: Main metabolite: 4-hydroxydebrisoquine.
CIMS Class
Other Antihypertensives
ATC Classification
C02CC04 - debrisoquine ; Belongs to the class of guanidine derivatives, peripherally-acting antiadrenergic agents. Used in the treatment of hypertension.
Disclaimer: This information is independently developed by CIMS based on debrisoquine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in